Bristol-Myers Squibb
Market Cap
US$150.8b
Last Updated
2021/07/31 22:15 UTC
Data Sources
Company Financials +
Executive Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential average dividend payer.
Similar Companies
Share Price & News
How has Bristol-Myers Squibb's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BMY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: BMY's weekly volatility (2%) has been stable over the past year.
Market Performance
7 Day Return
-0.7%
BMY
-0.01%
US Pharmaceuticals
-0.5%
US Market
1 Year Return
15.7%
BMY
17.5%
US Pharmaceuticals
35.9%
US Market
Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned 17.5% over the past year.
Return vs Market: BMY underperformed the US Market which returned 35.9% over the past year.
Shareholder returns
| BMY | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.7% | -0.01% | -0.5% |
| 30 Day | 2.0% | 2.7% | 0.09% |
| 90 Day | 8.7% | 9.3% | 3.2% |
| 1 Year | 19.3%15.7% | 22.4%17.5% | 38.0%35.9% |
| 3 Year | 26.0%14.7% | 33.4%22.0% | 62.8%52.6% |
| 5 Year | 24.3%7.3% | 49.1%29.9% | 121.2%96.9% |
Long-Term Price Volatility Vs. Market
How volatile is Bristol-Myers Squibb's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Did Bristol-Myers Squibb's (NYSE:BMY) Share Price Deserve to Gain 14%?1 month ago | Simply Wall St
Here's Why We're Wary Of Buying Bristol-Myers Squibb's (NYSE:BMY) For Its Upcoming Dividend1 month ago | Simply Wall St
Have Insiders Been Selling Bristol-Myers Squibb Company (NYSE:BMY) Shares?Valuation
Is Bristol-Myers Squibb undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMY ($67.87) is trading below our estimate of fair value ($191)
Significantly Below Fair Value: BMY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: BMY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BMY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BMY is overvalued based on its PB Ratio (4.1x) compared to the US Pharmaceuticals industry average (2.9x).
Future Growth
How is Bristol-Myers Squibb forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
52.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: BMY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BMY's is expected to become profitable in the next 3 years.
Revenue vs Market: BMY's revenue (3% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: BMY's revenue (3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMY's Return on Equity is forecast to be very high in 3 years time (46.8%).
Past Performance
How has Bristol-Myers Squibb performed over the past 5 years?
-45.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMY is currently unprofitable.
Growing Profit Margin: BMY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BMY is unprofitable, and losses have increased over the past 5 years at a rate of 45.7% per year.
Accelerating Growth: Unable to compare BMY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.9%).
Return on Equity
High ROE: BMY has a negative Return on Equity (-13.72%), as it is currently unprofitable.
Financial Health
How is Bristol-Myers Squibb's financial position?
Financial Position Analysis
Short Term Liabilities: BMY's short term assets ($29.2B) exceed its short term liabilities ($19.0B).
Long Term Liabilities: BMY's short term assets ($29.2B) do not cover its long term liabilities ($54.9B).
Debt to Equity History and Analysis
Debt Level: BMY's debt to equity ratio (122.5%) is considered high.
Reducing Debt: BMY's debt to equity ratio has increased from 44.7% to 122.5% over the past 5 years.
Debt Coverage: BMY's debt is well covered by operating cash flow (27.7%).
Interest Coverage: BMY's interest payments on its debt are well covered by EBIT (6.4x coverage).
Balance Sheet
Dividend
What is Bristol-Myers Squibb current dividend yield, its reliability and sustainability?
2.89%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BMY's dividend (2.89%) is higher than the bottom 25% of dividend payers in the US market (1.31%).
High Dividend: BMY's dividend (2.89%) is low compared to the top 25% of dividend payers in the US market (3.54%).
Stability and Growth of Payments
Stable Dividend: BMY's dividends per share have been stable in the past 10 years.
Growing Dividend: BMY's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: BMY is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: BMY's dividends in 3 years are forecast to be well covered by earnings (26% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.0yrs
Average management tenure
CEO
Giovanni Caforio (56 yo)
6.17yrs
Tenure
US$20,150,902
Compensation
Dr. Giovanni Caforio, M.D., serves as the Chief Executive Officer at Bristol-Myers Squibb Belgium NV/SA. He serves as Member of Business Roundtable and Chief Executive Officer Roundtable on Cancer. Dr. Caf...
CEO Compensation Analysis
Compensation vs Market: Giovanni's total compensation ($USD20.15M) is above average for companies of similar size in the US market ($USD11.17M).
Compensation vs Earnings: Giovanni's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: BMY's management team is seasoned and experienced (5 years average tenure).
Board Members
Experienced Board: BMY's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BMY insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Bristol-Myers Squibb Company's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bristol-Myers Squibb Company
- Ticker: BMY
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$150.815b
- Shares outstanding: 2.22b
- Website: https://www.bms.com
Number of Employees
Location
- Bristol-Myers Squibb Company
- 430 East 29th Street
- 14th Floor
- New York
- New York
- 10016
- United States
Listings
Biography
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunolo...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/07/31 22:15 |
| End of Day Share Price | 2021/07/30 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.